← All trials
NCT06461078
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2024
- Primary completion
- Sep 3, 2024
- Completion date
- Jun 30, 2025
- First posted
- Jun 14, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Il-Yang Pharm. Co., Ltd.Lead sponsor
- Yonsei UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.